U.S. regulators on Friday approved AbbVie Inc.’s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.. The U.S. Food and Drug Administration approved AbbVie’s Viekira Pak, an all-oral cocktail of several drugs that cured more than 90% of people with the most common subtype of hepatitis C in the U.S., genotype 1, in clinical trials. The regimen consists of several pills taken daily for about 12 weeks for most patients, eliminating the need for an older...
  